149 recruiting. 149 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 149 | Recruiting 149 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-23 |
| Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) CE1226 - Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency | Phase 4 | Recruiting | CSL Behring | 270 | 2026-09-29 | 2026-10-16 |
| Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® TyboWe® Adalimumab Injection - Crohn's Disease | Phase 4 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 50 | 2026-09-23 | 2026-09-24 |
| Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Elexacaftor, Tezacaftor, Ivacaftor, Ivacaftor (VX-770) - Cystic Fibrosis (CF) | Phase 4 | Recruiting | Istituto Giannina Gaslini | 50 | 2026-09-18 | 2026-10-14 |
| Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine N-Acetylcysteine (NAC) Treatment - Sepsis, Acute Infection | Phase 4 | Recruiting | Theis S. Itenov | 360 | 2026-09-07 | 2026-09-16 |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) Mazdutide, Placebo (Normal Saline), Lifestyle Optimization - Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis | Phase 4 | Recruiting | West China Hospital | 60 | 2026-09-01 | 2026-09-23 |
| Time to Loss of Consciousness With Remimazolam Versus Propofol for Anesthetic Induction in Laparoscopic Cholecystectomy Remimazolam, Propofol - Intravenous Anesthesia, Cholelithiasis | Phase 4 | Recruiting | Universidade Federal de Sergipe | 66 | 2026-08-21 | 2026-10-20 |
| A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative | Phase 4 | Recruiting | Janssen Research & Development, LLC | 10 | 2026-08-07 | 2026-11-03 |
| A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication Mirikizumab - Lactation, Inflammatory Bowel Disease | Phase 4 | Recruiting | Eli Lilly and Company | 14 | 2026-08-05 | 2026-11-04 |
| Stopping PPI Therapy in Inactive IBD Continue PPI Therapy, Withdraw PPI Therapy - Ulcerative Colitis (UC), Crohn's Disease | Phase 4 | Recruiting | University of Nottingham | 80 | 2026-07-01 | 2026-07-08 |
| Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Guselkumab - Crohn Disease (CD), Intensification | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 210 | 2026-06-18 | 2026-06-30 |
| A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2) - Biliary Tract Cancer (BTC) | Phase 4 | Recruiting | Xianglin Yuan | 32 | 2026-06-10 | 2026-09-15 |
| Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease Mirikizumab - IV, Mirikizumab - SC - Crohn Disease (CD) | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 75 | 2026-05-11 | 2026-11-04 |
| Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency Vitamin D2, Calcitriol - Cholestatic Liver Disease, Chronic Liver Disease (CLD) | Phase 4 | Recruiting | Chulalongkorn University | 54 | 2026-04-28 | 2026-08-03 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Guselkumab, Diet - Pouchitis | Phase 4 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 20 | 2026-04-23 | 2026-05-05 |
| Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD Mirikizumab - Crohn Disease | Phase 4 | Recruiting | Alimentiv Inc. | 60 | 2026-04-20 | 2026-10-26 |
| Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis Pancreatic Enzyme Replacement Therapy, Placebo, MBT1 - Chronic Pancreatitis, Recurrent Acute Pancreatitis | Phase 4 | Recruiting | Anna Evans Phillips | 80 | 2026-04-20 | 2026-09-11 |
| Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis Apixaban, Carvedilol, Placebo - Cirrhosis, Esophageal and Gastric Varices | Phase 4 | Recruiting | Asian Institute Of Medical Sciences | 220 | 2026-04-01 | 2026-04-09 |
| Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant Atezolizumab, Bevacizumab, Y^90 Radioembolization - Hepatocellular Carcinoma | Phase 4 | Recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-03-26 | 2026-07-28 |
Showing 20 of 149. Sign in to see all of them.
Crohn Disease (22) · Colitis, Ulcerative (15) · Carcinoma, Hepatocellular (10) · Gastroesophageal Reflux (8) · Liver Cirrhosis (8) · Colorectal Neoplasms (7) · Fibrosis (7) · Hepatitis B, Chronic (6) · Pancreatitis (6) · Cystic Fibrosis (5) · Hepatitis B (5) · Hypertension, Portal (5) · Liver Diseases (5) · Peptic Ulcer (5) · Stomach Neoplasms (5)
Gastrointestinal Diseases (83) · Intestinal Diseases (62) · Pathological Conditions, Signs and Symptoms (50) · Liver Diseases (42) · Gastroenteritis (40) · Pathologic Processes (38) · Neoplasms by Site (35) · Digestive System Neoplasms (34) · Neoplasms (34) · Inflammatory Bowel Diseases (29) · Colonic Diseases (24) · Infections (21) · Esophageal Diseases (18) · Pancreatic Diseases (17)
Infliximab (6) · vedolizumab (6) · Esomeprazole (5) · 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (4) · Adalimumab (4) · Carvedilol (4) · Rifaximin (4) · entecavir (4) · guselkumab (4) · Enoxaparin (3) · Omeprazole (3) · Ustekinumab (3) · mirikizumab (3) · Bevacizumab (2) · Bismuth (2)
Chinese University of Hong Kong (3) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (3) · Sixth Affiliated Hospital, Sun Yat-sen University (3) · Taipei Veterans General Hospital, Taiwan (3) · Universitaire Ziekenhuizen KU Leuven (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Alimentiv Inc. (2) · Bausch Health Americas, Inc. (2) · Children's Hospital of Fudan University (2) · Helsinki University Central Hospital (2) · Medical University of Warsaw (2) · Peking Union Medical College Hospital (2) · Ruijin Hospital (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Takeda (2)
United States (40) · China (35) · Canada (12) · France (9) · Belgium (8) · Germany (8) · Italy (8) · Denmark (7) · Netherlands (6) · Taiwan (6) · Brazil (5) · Poland (5) · South Korea (5) · Spain (5) · Egypt (4)
Duowu Zou, Doctor (2) · Ying Huang (2) · Albrecht Hoffmeister, Prof.Dr.med. (1) · Alexandra Kautzky-Willer, MD (1) · Ali Aminian, MD (1) · Amit Singal, MD, MS (1) · Anand Jain, MD (1) · Anna E Phillips, MD MS (1) · Annick Moens, MD, PhD (1) · Ansgar W Lohse, MD (1) · Anton Bermont, MD (1) · Aya Hany Abdel Aziz (1) · Baofeng Zhu, MD (1)
PMID 12518122, PMID 15505289, PMID 15565615, PMID 16310551, PMID 16525138, PMID 16879891, PMID 16923481, PMID 18519429, PMID 19052126, PMID 19140238, PMID 19410035, PMID 19670137, PMID 22668640, PMID 23100216, PMID 23186377, PMID 23732715, PMID 23840211, PMID 25088919, PMID 25476749, PMID 25579870, PMID 25872171, PMID 26389937, PMID 27057870, PMID 27322530, PMID 28196012, PMID 28404091, PMID 28404092, PMID 28427875, PMID 28655595, PMID 28682990, PMID 28697126, PMID 28801429, PMID 28848511, PMID 29289383, PMID 29364196, PMID 29405329, PMID 29696665, PMID 30094622, PMID 30629026, PMID 30719003, PMID 30979521, PMID 31011303, PMID 31227582, PMID 31229460, PMID 31268977, PMID 31592079, PMID 32476785, PMID 32617767, PMID 32632561, PMID 32798493
2025 (5), 2019 (2), 2023 (2), 2017 (1), 2018 (1), K12TR004908 (1), K23DK131317 (1), R01DK129676 (1), R01DK139089 (1), R01DK140381 (1), R01HL171034 (1), R03DK140415 (1), R03DK145962 (1), R34DA061732 (1), U24CA086368 (1)